top of page

Amgen's Xgeva matches zoledronic acid in phase 3 trial in multiple myeloma-related bone complica

A phase 3 study assessing Amgen’s Xgeva (denosumab) compared to zoledronic acid (ZA) for the prevention of bone complications in newly diagnosed multiple myeloma (MM) patients met its primary endpoint.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page